Literature DB >> 27528275

Inhibition of P2X Receptors Protects Human Monocytes against Damage by Leukotoxin from Aggregatibacter actinomycetemcomitans and α-Hemolysin from Escherichia coli.

Steen K Fagerberg1, Martin R Jakobsen1, Marianne Skals1, Helle A Praetorius2.   

Abstract

α-Hemolysin (HlyA) from Escherichia coli and leukotoxin A (LtxA) from Aggregatibacter actinomycetemcomitans are important virulence factors in ascending urinary tract infections and aggressive periodontitis, respectively. The extracellular signaling molecule ATP is released immediately after insertion of the toxins into plasma membranes and, via P2X receptors, is essential for the erythrocyte damage inflicted by these toxins. Moreover, ATP signaling is required for the ensuing recognition and phagocytosis of damaged erythrocytes by the monocytic cell line THP-1. Here, we investigate how these toxins affect THP-1 monocyte function. We demonstrate that both toxins trigger early ATP release and a following increase in the intracellular Ca2+ concentration ([Ca2+]i) in THP-1 monocytes. The HlyA- and LtxA-induced [Ca2+]i response is diminished by the P2 receptor antagonist in a pattern that fits the functional P2 receptor expression in these cells. Both toxins are capable of lysing THP-1 cells, with LtxA being more aggressive. Either desensitization or blockage of P2X1, P2X4, or P2X7 receptors markedly reduces toxin-induced cytolysis. This pattern is paralleled in freshly isolated human monocytes from healthy volunteers. Interestingly, only a minor fraction of the toxin-damaged THP-1 monocytes eventually lyse. P2X7 receptor inhibition generally prevents cell damage, except from a distinct cell shrinkage that prevails in response to the toxins. Moreover, we find that preexposure to HlyA preserves the capacity of THP-1 monocytes to phagocytose damaged erythrocytes and may induce readiness to discriminate between damaged and healthy erythrocytes. These findings suggest a new pharmacological target for protecting monocytes during exposure to pore-forming cytolysins during infection or injury.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27528275      PMCID: PMC5067745          DOI: 10.1128/IAI.00674-16

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  83 in total

1.  Python erythrocytes are resistant to α-hemolysin from Escherichia coli.

Authors:  Casper K Larsen; Marianne Skals; Tobias Wang; Muhammad U Cheema; Jens Leipziger; Helle A Praetorius
Journal:  J Membr Biol       Date:  2011-11-08       Impact factor: 1.843

2.  RTX toxins recognize a beta2 integrin on the surface of human target cells.

Authors:  E T Lally; I R Kieba; A Sato; C L Green; J Rosenbloom; J Korostoff; J F Wang; B J Shenker; S Ortlepp; M K Robinson; P C Billings
Journal:  J Biol Chem       Date:  1997-11-28       Impact factor: 5.157

3.  Purinoceptors are involved in the induction of an osmolyte permeability in malaria-infected and oxidized human erythrocytes.

Authors:  Valérie Tanneur; Christophe Duranton; Verena B Brand; Ciprian D Sandu; Canan Akkaya; Ravi S Kasinathan; Christian Gachet; Ronald Sluyter; Julian A Barden; James S Wiley; Florian Lang; Stephan M Huber
Journal:  FASEB J       Date:  2005-11-02       Impact factor: 5.191

4.  Regulation of Actinobacillus actinomycetemcomitans leukotoxin expression: analysis of the promoter regions of leukotoxic and minimally leukotoxic strains.

Authors:  J M Brogan; E T Lally; K Poulsen; M Kilian; D R Demuth
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

5.  Leukotoxin from Aggregatibacter actinomycetemcomitans causes shrinkage and P2X receptor-dependent lysis of human erythrocytes.

Authors:  Peter Svenssen Munksgaard; Thomas Vorup-Jensen; Jesper Reinholdt; Carl Martin Söderström; Knud Poulsen; Jens Leipziger; Helle A Praetorius; Marianne Skals
Journal:  Cell Microbiol       Date:  2012-09-25       Impact factor: 3.715

6.  Direct modulation of P2X1 receptor-channels by the lipid phosphatidylinositol 4,5-bisphosphate.

Authors:  Louis-Philippe Bernier; Ariel R Ase; Xinkang Tong; Edith Hamel; Dominique Blais; Qi Zhao; Diomedes E Logothetis; Philippe Séguéla
Journal:  Mol Pharmacol       Date:  2008-06-03       Impact factor: 4.436

7.  Alpha-hemolysin from Escherichia coli uses endogenous amplification through P2X receptor activation to induce hemolysis.

Authors:  Marianne Skals; Niklas R Jorgensen; Jens Leipziger; Helle A Praetorius
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-18       Impact factor: 11.205

8.  Serogroups and virulence genotypes of Escherichia coli isolated from patients with sepsis.

Authors:  M Ananias; T Yano
Journal:  Braz J Med Biol Res       Date:  2008-10       Impact factor: 2.590

9.  Aggregatibacter actinomycetemcomitans leukotoxin requires beta-sheets 1 and 2 of the human CD11a beta-propeller for cytotoxicity.

Authors:  Irene R Kieba; Karen P Fong; Hsin-Yao Tang; Karl E Hoffman; David W Speicher; Lloyd B Klickstein; Edward T Lally
Journal:  Cell Microbiol       Date:  2007-06-24       Impact factor: 3.715

10.  P2X1 and P2X4 receptor currents in mouse macrophages.

Authors:  J A Sim; C-K Park; S B Oh; R J Evans; R A North
Journal:  Br J Pharmacol       Date:  2007-10-15       Impact factor: 8.739

View more
  13 in total

Review 1.  Aggregatibacter actinomycetemcomitans leukotoxin: From mechanism to targeted anti-toxin therapeutics.

Authors:  Eric Krueger; Angela C Brown
Journal:  Mol Oral Microbiol       Date:  2020-03-10       Impact factor: 3.563

2.  Receptor-Based Peptides for Inhibition of Leukotoxin Activity.

Authors:  Eric Krueger; Shannon Hayes; En Hyung Chang; Shailagne Yutuc; Angela C Brown
Journal:  ACS Infect Dis       Date:  2018-05-17       Impact factor: 5.084

Review 3.  P2RX7 at the Host-Pathogen Interface of Infectious Diseases.

Authors:  Alexandra Y Soare; Tracey L Freeman; Alice K Min; Hagerah S Malik; Elizabeth O Osota; Talia H Swartz
Journal:  Microbiol Mol Biol Rev       Date:  2021-01-13       Impact factor: 11.056

Review 4.  Kingella kingae RtxA Cytotoxin in the Context of Other RTX Toxins.

Authors:  Katerina Filipi; Waheed Ur Rahman; Adriana Osickova; Radim Osicka
Journal:  Microorganisms       Date:  2022-02-27

5.  P2X1, P2X4, and P2X7 Receptor Knock Out Mice Expose Differential Outcome of Sepsis Induced by α-Haemolysin Producing Escherichia coli.

Authors:  Anne-Sofie Greve; Marianne Skals; Steen K Fagerberg; Wulf Tonnus; Svend Ellermann-Eriksen; Richard J Evans; Andreas Linkermann; Helle A Praetorius
Journal:  Front Cell Infect Microbiol       Date:  2017-04-06       Impact factor: 5.293

6.  α-Hemolysin of uropathogenic E. coli regulates NLRP3 inflammasome activation and mitochondrial dysfunction in THP-1 macrophages.

Authors:  Vivek Verma; Parveen Kumar; Surbhi Gupta; Sonal Yadav; Rakesh Singh Dhanda; Henrik Thorlacius; Manisha Yadav
Journal:  Sci Rep       Date:  2020-07-28       Impact factor: 4.379

7.  Shiga toxin signals via ATP and its effect is blocked by purinergic receptor antagonism.

Authors:  Karl E Johansson; Anne-Lie Ståhl; Ida Arvidsson; Sebastian Loos; Ashmita Tontanahal; Johan Rebetz; Milan Chromek; Ann-Charlotte Kristoffersson; Ludger Johannes; Diana Karpman
Journal:  Sci Rep       Date:  2019-10-07       Impact factor: 4.379

Review 8.  Aggregatibacter actinomycetemcomitans Leukotoxin (LtxA; Leukothera®): Mechanisms of Action and Therapeutic Applications.

Authors:  Brian A Vega; Benjamin A Belinka; Scott C Kachlany
Journal:  Toxins (Basel)       Date:  2019-08-26       Impact factor: 4.546

9.  Alpha-hemolysin of uropathogenic Escherichia coli induces GM-CSF-mediated acute kidney injury.

Authors:  Changying Wang; Qianqian Li; Junqiang Lv; Xuan Sun; Yang Cao; Kaiyuan Yu; Chunhui Miao; Zhi-Song Zhang; Zhi Yao; Quan Wang
Journal:  Mucosal Immunol       Date:  2019-11-12       Impact factor: 7.313

Review 10.  RTX Toxins Ambush Immunity's First Cellular Responders.

Authors:  Laura C Ristow; Rodney A Welch
Journal:  Toxins (Basel)       Date:  2019-12-10       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.